Role of Inflammatory Cytokines in Rheumatoid Arthritis and Development of Atherosclerosis: A Review

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2023 Sep 28

PMID 37763669

Authors

Drazen Bedekovic

Ivica Bosnjak

Sandra Saric

Damir Kirner

Srdan Novak

Affiliations

Soon will be listed here.

Abstract

Uncontrolled chronic inflammation results in cardiovascular disease and early death. In this review, we studied the impact of rheumatoid arthritis on the cardiovascular system, including the early and accelerated development of atherosclerosis and its clinical manifestations, focusing on the inflammatory mechanisms leading to arterial wall damage, rapid atherosclerotic plaque formation, and thrombosis. Furthermore, the effect of medications used to treat rheumatoid arthritis on the cardiovascular system was studied. The effect of chronic inflammation and medication on traditional cardiovascular risk factors is not the main subject of this review. We observed that uncontrolled chronic inflammation and some medications directly impact all the stages of atherosclerosis. In conclusion, reducing inflammation and maintaining long-term remission in rheumatoid arthritis may prevent early atherosclerosis. We believe that this review will encourage a better interdisciplinary approach to the management of these patients and further research in this field.

Citing Articles

Interleukin-6: Cardiovascular Aspects of Long-Term Cytokine Suppression in Patients with Rheumatoid Arthritis.

Gerasimova E, Popkova T, Kirillova I, Gerasimova D, Nasonov E, Lila A Int J Mol Sci. 2024; 25(22).

PMID: 39596487 PMC: 11594593. DOI: 10.3390/ijms252212425.

miR-6089 may prevent the inflammatory events leading to cardiovascular disorders in RA patients.

Shamsi A, Roghani S, Shamsi M, Jalili C, Taghadosi M, Soufivand P Heliyon. 2024; 10(17):e36763.

PMID: 39281435 PMC: 11395719. DOI: 10.1016/j.heliyon.2024.e36763.

Emerging Landscape of Models for Assessing Rheumatoid Arthritis Management.

Mishra A, Kumar R, Harilal S, Nigam M, Datta D, Singh S ACS Pharmacol Transl Sci. 2024; 7(8):2280-2305.

PMID: 39144547 PMC: 11320735. DOI: 10.1021/acsptsci.4c00260.

Treating Cardiovascular Disease in the Inflammatory Setting of Rheumatoid Arthritis: An Ongoing Challenge.

Godbole S, Solomon J, Johnson M, Srivastava A, Carsons S, Belilos E Biomedicines. 2024; 12(7).

PMID: 39062180 PMC: 11275112. DOI: 10.3390/biomedicines12071608.

A Review of Advances in Molecular Imaging of Rheumatoid Arthritis: From In Vitro to Clinic Applications Using Radiolabeled Targeting Vectors with Technetium-99m.

Ali M, Benfante V, Di Raimondo D, Laudicella R, Tuttolomondo A, Comelli A Life (Basel). 2024; 14(6).

PMID: 38929734 PMC: 11204982. DOI: 10.3390/life14060751.

References

Rincon-Lopez E, Navarro Gomez M, Hernandez-Sampelayo Matos T, Aguilera-Alonso D, Duenas Moreno E, Saavedra-Lozano J . Interleukin 6 as a marker of severe bacterial infection in children with sickle cell disease and fever: a case-control study. BMC Infect Dis. 2021; 21(1):741. PMC: 8329904. DOI: 10.1186/s12879-021-06470-4. View

Mewar D, Coote A, Moore D, Marinou I, Keyworth J, Dickson M . Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis Res Ther. 2006; 8(4):R128. PMC: 1779371. DOI: 10.1186/ar2017. View

Karpouzas G, Ormseth S, Hernandez E, Budoff M . Impact of Cumulative Inflammation, Cardiac Risk Factors, and Medication Exposure on Coronary Atherosclerosis Progression in Rheumatoid Arthritis. Arthritis Rheumatol. 2019; 72(3):400-408. DOI: 10.1002/art.41122. View

Souto A, Salgado E, Maneiro J, Mera A, Carmona L, Gomez-Reino J . Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol. 2014; 67(1):117-27. DOI: 10.1002/art.38894. View

Solomon D, Avorn J, Katz J, Weinblatt M, Setoguchi S, Levin R . Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 2006; 54(12):3790-8. DOI: 10.1002/art.22255. View

Goodson N, Brookhart A, Symmons D, Silman A, Solomon D . Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis. 2008; 68(3):367-72. PMC: 2633631. DOI: 10.1136/ard.2007.076760. View

Gargiulo G, Capodanno D, Longo G, Capranzano P, Tamburino C . Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes. Expert Rev Cardiovasc Ther. 2014; 12(10):1185-203. DOI: 10.1586/14779072.2014.964687. View

McInnes I, Thompson L, Giles J, Bathon J, Salmon J, Beaulieu A . Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2013; 74(4):694-702. PMC: 4392313. DOI: 10.1136/annrheumdis-2013-204345. View

Charles-Schoeman C, Wang X, Lee Y, Shahbazian A, Navarro-Millan I, Yang S . Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheumatol. 2015; 68(3):577-86. PMC: 4774543. DOI: 10.1002/art.39502. View

10.

Widdifield J, Abrahamowicz M, Paterson J, Huang A, Thorne J, Pope J . Associations Between Methotrexate Use and the Risk of Cardiovascular Events in Patients with Elderly-onset Rheumatoid Arthritis. J Rheumatol. 2018; 46(5):467-474. DOI: 10.3899/jrheum.180427. View

11.

Innala L, Moller B, Ljung L, Magnusson S, Smedby T, Sodergren A . Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther. 2011; 13(4):R131. PMC: 3239373. DOI: 10.1186/ar3442. View

12.

Agca R, Heslinga S, Rollefstad S, Heslinga M, McInnes I, Peters M . EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2016; 76(1):17-28. DOI: 10.1136/annrheumdis-2016-209775. View

13.

Sakai R, Hirano F, Kihara M, Yokoyama W, Yamazaki H, Harada S . High prevalence of cardiovascular comorbidities in patients with rheumatoid arthritis from a population-based cross-sectional study of a Japanese health insurance database. Mod Rheumatol. 2015; 26(4):522-8. DOI: 10.3109/14397595.2015.1106682. View

14.

Jiang P, Li H, Li X . Diabetes mellitus risk factors in rheumatoid arthritis: a systematic review and meta-analysis. Clin Exp Rheumatol. 2014; 33(1):115-21. View

15.

Sokka T, Abelson B, Pincus T . Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol. 2008; 26(5 Suppl 51):S35-61. View

16.

Habets K, Trouw L, Levarht E, Korporaal S, Habets P, de Groot P . Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis. Arthritis Res Ther. 2015; 17:209. PMC: 4548712. DOI: 10.1186/s13075-015-0665-7. View

17.

Gregersen P, Silver J, Winchester R . The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987; 30(11):1205-13. DOI: 10.1002/art.1780301102. View

18.

Welsing P, van Gestel A, Swinkels H, Kiemeney L, van Riel P . The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum. 2001; 44(9):2009-17. DOI: 10.1002/1529-0131(200109)44:9<2009::AID-ART349>3.0.CO;2-L. View

19.

Schiff M, Kremer J, Jahreis A, Vernon E, Isaacs J, van Vollenhoven R . Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011; 13(5):R141. PMC: 3308069. DOI: 10.1186/ar3455. View

20.

Soubrier M, Barber Chamoux N, Tatar Z, Couderc M, Dubost J, Mathieu S . Cardiovascular risk in rheumatoid arthritis. Joint Bone Spine. 2014; 81(4):298-302. DOI: 10.1016/j.jbspin.2014.01.009. View